Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation for Risk Reduction

"Affirmative. Clinicaltrials.gov verifies that this clinical trial, which was first announced on August 15th 2022, is actively seeking participants. The researchers are looking for 80 patients at a single medical facility."

"Affirmative. Clinicaltrials.gov records indicate that this clinical trial, posted on August 15th 2022, is proactively recruiting individuals for participation. 80 subjects are being accepted at 1 medical facility."

"For this trial, 80 participants aged 18-49 who are at risk of reduction must be recruited. These individuals should also meet the following requirements: female candidates of childbearing potential need to agree to acceptable birth control measures; demonstrate an ability to provide written informed consent; present good general health as determined by vitals and medical history (including a physical examination within 45 days prior); display expressed interest in fulfilling study requisites; abstain from participating in other clinical trials throughout the duration of the experiment; and allow for indefinite storage of stored blood samples used for research purposes."

"This clinical trial has stipulated that participants must be between 18 and 49 years old, as indicated by the established inclusion criteria."

"The estimated safety of Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation is a 1 due to the lack of empirical evidence supporting its efficacy and security, as this trial is in Phase 1."